Objective: To assess the efficacy and safety of a new medical device (MD; a capsule whose main component is a cross-linked protein) in the prevention of uncomplicated cystitis recurrences. Methods: Adult women with acute cystitis symptoms and a ciprofloxacin-susceptible isolate in urine culture were included in a randomized, double-blind clinical trial. Patients were treated with ciprofloxacin 500 mg/day and 1 capsule/day or matched placebo for 5 days, 1 capsule/day or placebo for 15 additional days, and 2 additional cycles of 1 capsule/day or placebo for 15 days on months 1 and 2 after initial treatment. Results: No recurrence was observed after the first month of follow-up in the MD-treated group. In addition, symptomatic recurrence was reduced by 19.4% compared with placebo after 6 months. Conclusions: The new MD can help prevent the recurrence of uncomplicated cystitis as well as help to reduce antibiotic use in management of urinary tract infection in women.

Keywords:
Urinary tract infections, Recurrence, Cystitis, Clinical trial
1.
Foxman B: Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am 2014;28:1-13.
2.
Foxman B: Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Dis Mon 2003;49:53-70.
3.
Schito GC, Naber KG, Botto H, Palou J, Mazzei T, Gualco L, Marchese A: The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents 2009;34:407-413.
4.
Andreu A: [Pathogenesis of urinary tract infections]. Enferm Infecc Microbiol Clin 2005;23(suppl 4):15-21.
5.
Bent S, Saint S: The optimal use of diagnostic testing in women with acute uncomplicated cystitis. Am J Med 2002;113(suppl 1A):20S-28S.
6.
Foxman B, Gillespie B, Koopman J, Zhang L, Palin K, Tallman P, Marsh JV, Spear S, Sobel JD, Marty MJ, Marrs CF: Risk factors for second urinary tract infection among college women. Am J Epidemiol 2000;151:1194-1205.
7.
Ronald A: The etiology of urinary tract infection: traditional and emerging pathogens. Am J Med 2002;113(suppl 1A):14S-19S.
8.
González-Chamorro F, Palacios R, Alcover J, Campos J, Borrego F, Dámaso D: [Urinary tract infections and their prevention]. Actas Urol Esp 2012;36:48-53.
9.
Hickling DR, Nitti VW: Management of recurrent urinary tract infections in healthy adult women. Rev Urol 2013;15:41-48.
10.
Carlet J, Collignon P, Goldmann D, Goossens H, Gyssens IC, Harbarth S, Jarlier V, Levy SB, N'Doye B, Pittet D, Richtmann R, Seto WH, van der Meer JW, Voss A: Society's failure to protect a precious resource: antibiotics. Lancet 2011;378:369-371.
11.
Oteo J, Pérez-Vázquez M, Campos J: Extended-spectrum [beta]-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr Opin Infect Dis 2010;23:320-326.
12.
Zowawi HM, Harris PN, Roberts MJ, Tambyah PA, Schembri MA, Pezzani MD, Williamson DA, Paterson DL: The emerging threat of multidrug-resistant Gram-negative bacteria in urology. Nat Rev Urol 2015;12:570-584.
13.
Kahlmeter G, Åhman J, Matuschek E: Antimicrobial resistance of Escherichia coli causing uncomplicated urinary tract infections: a European update for 2014 and comparison with 2000 and 2008. Infect Dis Ther 2015;4:417-423.
14.
Prieto L, Esteban M, Salinas J, Adot JM, Arlandis S, Peri L, Cozar JM: Consensus document of the Spanish urological association on the management of uncomplicated recurrent urinary tract infections. Actas Urol Esp 2015;39:339-348.
15.
García-Larrosa A, Alexe O: [Utipro®: a new, effective treatment against acute cystitis symptoms]. Tenerife, LXXIX Congreso Nacional de Urología, June 11-14, 2014, p 118.
16.
Albert X, Huertas I, Pereiró II, Sanfélix J, Gosalbes V, Perrota C: Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev 2004;3:CD001209.
17.
Ruszczyński M, Urbańska M, Szajewska H: Gelatin tannate for treating acute gastroenteritis: a systematic review. Ann Gastroenterol 2014;27:121-124.
18.
Ndu OO, Nworu CS, Ehiemere CO, Ndukwe NC, Ochiogu IS: Herb-drug interaction between the extract of Hibiscus sabdariffa L. and hydrochlorothiazide in experimental animals. J Med Food 2011;14:640-644.
19.
Carlsson S, Wiklund NP, Engstrand L, Weitzberg E, Lundberg JO: Effects of pH, nitrite, and ascorbic acid on nonenzymatic nitric oxide generation and bacterial growth in urine. Nitric Oxide 2001;5:580-586.
20.
Serban C, Sahebkar A, Ursoniu S, Andrica F, Banach M: Effect of sour tea (Hibiscus sabdariffa L.) on arterial hypertension: a systematic review and meta-analysis of randomized controlled trials. J Hypertens 2015;33:1119-1127.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.